Fulcrum Therapeutics (FULC) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 17.0% versus a loss of 61.1%. Over five years, VNDA leads with a -75.4% price change compared with -85.9% for FULC. Fulcrum Therapeutics is the larger company by market cap ($285.7 million vs $273.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | VNDA |
|---|---|---|
| Share price | $3.75 | $4.53 |
| Market cap | $285.73M | $273.59M |
| 1-day change | -0.13% | -0.11% |
| YTD return | -66.84% | -48.64% |
| 1-year return | -61.06% | -17.03% |
| 5-year return | -85.88% | -75.39% |
| Forward P/E | — | 22.63 |
| EPS (TTM) | $-1.21 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $9.94 |
| 52-week low | $2.83 | $4.27 |
| Distance from 52-week high | -76.21% | -54.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -2.00% | +159.67% |
| Average volume | 1.54M | 974.13K |
| Shares outstanding | 76.30M | 60.46M |
| Employees | 9 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed FULC by 44.0 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
FULC vs VNDA FAQ
Which is bigger, Fulcrum Therapeutics or Vanda Pharmaceuticals?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $285.73M compared with $273.59M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, FULC or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -61.06% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.